Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
Delta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) is heterogeneous and not well characterized. We describe the landscape of DLL3 at the mRNA and protein levels across SCLC, large cell neuroendocrine carcinoma (LCNEC), and non-small cell lung cancer. Additionally, we explore its expression in extra-pulmonary NEN (EP-NEN) using a standardized DLL3 IHC assay. DLL3 expression is enriched in SCLC, LCNEC along with combined histology lung cancers. Moreover, we find a wide range of DLL3 expression in high-grade EP-NEN. We describe heterogenous DLL3 expression not only in SCLC but also in different NEN types. This comprehensive characterization of DLL3 can help guide future clinical trial design targeting DLL3 in NEN including LCNEC and EP-NEN that are lacking standard of care treatment options.
Authors
- Preetha Ramalingam (ORCID: https://orcid.org/0000-0002-4816-507X)
- Wei Lu (ORCID: https://orcid.org/0000-0002-1316-6574)
- Daniel M. Halperin (ORCID: https://orcid.org/0000-0002-3113-930X)
- Aaron R. Ellison
- Khaja Khan
- Bingnan Zhang (ORCID: https://orcid.org/0000-0002-1821-6243)
- Ana Maria Aparicio (ORCID: https://orcid.org/0000-0003-0900-0923)
- C. Allison Stewart (ORCID: https://orcid.org/0000-0002-7758-1179)
- Ignacio I. Wistuba (ORCID: https://orcid.org/0000-0003-3365-6340)
- Kyle Concannon (ORCID: https://orcid.org/0000-0001-8445-6328)
- Alejandra G. Serrano (ORCID: https://orcid.org/0000-0001-6759-9239)
- Sharia Hernandez (ORCID: https://orcid.org/0000-0002-7746-0860)
- Kanishka Sircar (ORCID: https://orcid.org/0000-0001-9515-697X)
- Pedro Rocha (ORCID: https://orcid.org/0000-0003-3221-7354)
- Alexander J. Lazar (ORCID: https://orcid.org/0000-0002-6395-4499)
- Carl M. Gay (ORCID: https://orcid.org/0000-0002-4907-0718)
- Lauren A. Byers (ORCID: https://orcid.org/0000-0002-0780-2677)
- Jeannelyn S. Estrella (ORCID: https://orcid.org/0000-0003-3705-5964)
- Adel K. El‐Naggar (ORCID: https://orcid.org/0000-0002-7175-9466)
- Luisa M. Solis Soto (ORCID: https://orcid.org/0000-0002-1253-630X)
- Junya Fujimoto (ORCID: https://orcid.org/0000-0003-4813-3163)
- Lixia Diao (ORCID: https://orcid.org/0000-0001-6995-4492)
- Robert J. Cardnell
- Kasey R. Cargill (ORCID: https://orcid.org/0000-0003-3082-1937)
- Miao Zhang (ORCID: https://orcid.org/0000-0003-4912-2570)
- Neda Kalhor (ORCID: https://orcid.org/0000-0001-6891-6435)
- Beate Sable
- Cibelle Freitas Lima
- C Bogdan
- Qi Wang (ORCID: https://orcid.org/0009-0004-6707-6613)
Institutions
- Amgen (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1038/s41698-024-00739-y
- Citations
- 18
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.09